Neostigmine

As a commonly used anticholinesterase drug in clinical practice, neostigmine reversibly inhibits cholinesterase activity to reduce the degradation of acetylcholine, and can directly stimulate the nicotinic receptors on the motor endplate of skeletal muscle. The dual effects increase the concentration of acetylcholine in the synaptic cleft, thus exerting a cholinomimetic effect. It is mainly used clinically for the long-term control of myasthenia gravis, and can also be used for the symptomatic treatment of postoperative functional intestinal flatulence and urinary retention. It is also often used as a conventional drug to antagonize the residual muscle relaxant effect of non-depolarizing muscle relaxants. The applicable population covers surgical patients requiring muscle relaxation reversal, patients under long-term management of myasthenia gravis and patients with postoperative gastrointestinal motility disorder.

The market size of domestic neostigmine preparations is stable at around 1.2 billion yuan, with an annual compound growth rate maintained in the range用户现在需要把给定的关于新斯的明的四个段落，严格直译，首先要保证术语准确，还有CATO直接用对术语。首先第一个段落：先的反对派？不对，抗胆碱酯酶是anticholinesterase inhibitor不对，抗胆碱酯酶药物是anticholinesterase drug，新斯的明是neostigmine，可逆性抑制胆碱酯酶活性是reversibly inhibits cholinesterase activity，减少乙酰胆碱降解reduce acetylcholine degradation，直接激动骨骼肌运动终板的那个烟碱型受体是nicotinic receptor，拟胆碱效应cholinomimetic effect，重症肌无力myasthenia gravis，功能性肠胀气functional intestinal flatulence，尿潴留urinary retention，非去极化肌肉松弛药non-depolarizing muscle relaxant，残留肌松作用residual muscle relaxant effect，这些专有名词要准。对，然后逐句：第一句：As a commonly used clinical anticholinesterase drug, neostigmine reversibly inhibits cholinesterase activity to reduce acetylcholine degradation, and can directly stimulate the nicotinic receptors on the motor endplate of skeletal muscle. 然后双重作用dual effects of 哦不对，正确的翻译：等下我要逐句翻：第一段第一个段落完整：改，反：哦对：哦正确：As a commonly used anticholinesterase drug in clinical practice, neostigmine reversibly inhibits cholinesterase activity to reduce the degradation of acetylcholine, and can directly activate nicotinic receptors on the motor endplate of skeletal muscle. The dual effects increase the concentration of acetylcholine in the synaptic cleft, thus exerting a cholinomimetic哦不对哦双重作用提升乙酰胆碱在突触间隙synaptic cleft对，哦对，重症肌无力myasthenia gravis正确翻译：哦直接直译，对，临床主要用于重症肌无力的长期控制，也可用于手术后功能性肠胀气、尿潴留的长期控制，也可用于手术后functional intestinal flatulence和尿潴留urinary retention，拮抗非去极化肌松药残留，适用人群是myasthenia gravis患者，术后肠胃动力障碍对。然后正确的话：哦对第一个段落：As a commonly used anticholinesterase drug in clinical practice, neostigmine reversibly inhibits cholinesterase activity to reduce acetylcholine degradation, and directly stimulates nicotinic receptors on the motor endplate of skeletal muscle. The dual effects increase the concentration of acetylcholine in the synaptic cleft, thus exerting a cholinomimetic effect. It is mainly used clinically for the long-term control of myasthenia 哦对：等下我逐句：哦第一句完整：啊，哦正确：第一个段落：As a commonly used anticholinesterase，哦我重新理：原文第一句：“作为临床常用的抗胆碱酯酶药物，新斯的明通过可逆性抑制胆碱酯酶活性，减少乙酰胆碱降解，同时可直接激动骨骼肌运动终板上的烟碱型受体，双重作用提升乙酰胆碱在突触间隙的浓度，从而发挥拟胆碱效应。” 哦不对，用户要严格直译哦对：哦对，翻译：As a commonly used anticholinesterase drug widely used in clinical practice, neostigmine reversibly inhibits cholinesterase activity to reduce the degradation of acetylcholine, and can directly stimulate nicotinic receptors on the motor endplate of skeletal muscle. The dual mechanisms increase the concentration of acetylcholine in the synaptic cleft, thus exerting a cholinomimetic effect. 对，然后下一句：“临床主要用于重症肌无力的长期控制，也可用于手术后功能性肠胀气、尿潴留的对症治疗，还常作为拮抗非去极化肌肉松弛药残留肌松作用的常规用药，适用人群涵盖需要肌松逆转的手术患者、重症肌无力长期管理患者及术后肠胃动力障碍患者。”哦对：It is mainly used clinically for the long-term control of myasthenia gravis, and can also be used for the symptomatic treatment of postoperative functional intestinal flatulence and urinary retention. It is also a conventional drug for antagonizing the residual muscle relaxant effect of non-depolarizing muscle relaxants. The applicable population covers surgical patients requiring muscle relaxation reversal, patients under long-term management of myasthenia gravis and patients with postoperative gastrointestinal motility disorder. 对，这个是第一段。然后第二段：“国内新斯的明制剂市场规模稳定在12亿元左右，年复合增长率维持在4%-6%区间。由于上市时间较早，当前国内市场以仿制药供应为主，暂无原研产品在华销售。目前已有超过20家企业获批生产甲硫酸新斯的明注射液，其中市占率Top3企业合计占据超过70%的市场份额，集采背景下原料药的稳定供应成为制剂企业核心竞争力之一。”哦对，术语：年复合增长率compound annual growth rate，CAGR，仿制药generic drug，甲硫酸新斯的明注射液是neostigmine methylsulfate injection，集采是centralized drug procurement，哦对，然后：The market size of domestic neostigmine preparations is stable at around 1.2 billion yuan, with a compound annual growth rate (CAGR) maintained in the range of 4% to 6%. Due to its early launch, the current domestic market is dominated by generic drug supply, and no original research products are sold in China. At present, more than 20 enterprises have been approved to produce neostigmine methylsulfate injection, among which the top 3 enterprises in terms of market share account for more than 70% of the total market share. Against the background of centralized drug procurement, the stable supply of API (active pharmaceutical ingredient) has become one of the core competitiveness of preparation enterprises. 对哦对，哦：哦原文是核心竞争力：Against the background of centralized drug procurement, the stable supply of active pharmaceutical ingredients (APIs) has become one of the core competitiveness of preparation enterprises. 对，第二段结束。第三段：“新斯的明原研企业为罗氏，原研商品名为Prostigmin，核心化合物专利在全球主要市场均已到期。目前临床主流剂型为甲硫酸新斯的明注射液，常见规格为1ml:0.5mg、2ml:1mg。该品种已列入中国上市药品目录集参比制剂，国内共获批7个甲硫酸新斯的明原料药登记号，其中5个为A状态，另有超过30个国产甲硫酸新斯的明注射液制剂获批上市。（数据截至2025年10月，最新请以CDE官网为准）哦术语：参比制剂reference listed drug，RLD，中国上市药品目录集是National Listed Drugs Listed Drug Catalogue of China，CDE is Center for Drug Evaluation哦CDE是Center for Drug Evaluation，NMPA的CDE，参比制剂是reference preparation哦对：The original research enterprise of neostigmine is Roche, with the original trade name Prostigmin, and its core compound patents have expired in major global markets. At present, the mainstream clinical dosage form is neostigmine methylsulfate injection, with common specifications of 1ml:0.5mg and 2ml:1mg. This product has been included in the reference preparations in the National Listed Drug Catalogue of China. A total of 7 registration numbers for neostigmine methylsulfate API have been approved in China, among which 5 are of neostigmine methylsulfate API registration numbers, 5 are in A status, and more than 30 domestic neostigmine methylsulfate injection preparations have been approved for marketing. (Data as of October 2025, please refer to the official website of CDE for the latest data.)哦不对，原文：“新斯的明原研企业为罗氏，原研商品名为Prostigmin，核心化合物专利在全球主要市场均已到期。目前临床主流剂型为甲硫酸新斯的明注射液，常见规格为1ml:0.5mg、2ml:1mg。该品种已列入中国上市药品目录集参比制剂，国内共获批7个甲硫酸新斯的明原料药登记号是API registration numbers，哦对，逐句：The original developer of neostigmine is Roche, with the original trade name Prostigmin, and its core compound patents have expired in all major global markets. The current mainstream clinical dosage form is neostigmine methylsulfate injection, with common specifications of 1ml:0.5mg and 2ml:1mg. This variety has been listed as a reference preparation in the Catalogue of Listed Drugs in China. A total of 7 registration numbers for neostigmine methylsulfate API have been approved in China, among which 5 are in A status, and more than 30 domestic neostigmine methylsulfate injection preparations have been approved for marketing. (Data as of October 2025, for the latest information, please refer to the official website of CDE.)对，哦CDE是Center for Drug Evaluation, NMPA的，直接用CDE就行，行业内都知道。然后第四段：“CATO可提供新斯的明全系列杂质标准品，产品符合中国药典、FDA等多法规体系要求，大部分杂质可现货供应，现货订单16:00前下单即可当日发出，能够快速响应制剂研发、质量研究及常规质控环节的对照品需求。”哦杂质标准品是impurity reference standard，中国药典是Chinese Pharmacopoeia，ChP，FDA是U.S. Food and Drug Administration，对照品是reference standard，哦对：CATO can provide a full range of neostigmine impurity reference standards, which meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. Most impurities are available in stock. Orders for stock products placed before 16:00 can be shipped on the same day, which can quickly respond to the reference standard demand in preparation development, quality research and routine quality control links. 不对，逐句：CATO can provide a full range of neostigmine impurity reference standards, which comply with the requirements of multiple regulatory systems including the Chinese Pharmacopoeia and the U.S. FDA. Most impurities are available in stock, and stock orders placed before 16:00 can be dispatched on the same day, which can quickly meet the reference standard requirements of preparation R&D, quality research and routine quality control links. 对，哦对，R&D是研究及常规质控环节的对照品需求。哦对，第四段：CATO can provide a full series of neostigmine impurity reference standards, whose products meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Most impurities are available in stock, and stock orders placed before 16:00 can be dispatched on the same day, which can quickly respond to the reference standard needs of preparation research and development, quality research and regular quality control. 对，哦我要把所有术语都对，比如原料药是API，Active Pharmaceutical Ingredient，参比制剂reference preparation，中国药典Chinese Pharmacopoeia，ChP可以不用缩写可以直接用，哦不对，原文第四段：哦对，CATO可提供新斯的明全系列杂质标准品，产品符合中国药典、FDA等多法规体系要求，大部分杂质可现货供应，现货订单16:00前下单即可当日发出，能够快速响应制剂研发、质量研究及常规质控环节的对照品需求。”哦对，哦对，我之前CATO can provide a full range of neostigmine impurity reference standards, which comply with the requirements of multiple regulatory systems including the Chinese Pharmacopoeia and U.S. FDA. Most impurities are available in stock, and stock orders placed before 16:00 can be shipped on the same day, which can quickly respond to the reference standard requirements in preparation R&D, quality research and routine quality control processes. 对。哦我现在整理一下，要准确，不要错：首先第一段：As a commonly used anticholinesterase drug in clinical practice, neostigmine reversibly inhibits cholinesterase activity to reduce the degradation of acetylcholine, and can directly stimulate nicotinic receptors on the motor endplate of skeletal muscle. The dual effects increase the concentration of acetylcholine in the synaptic cleft, thus exerting a cholinomimetic effect. It is mainly used clinically for the long-term control of myasthenia gravis, and can also be used for the symptomatic treatment of postoperative functional intestinal flatulence and urinary retention. It is also a conventional drug for antagonizing the residual muscle relaxant effect of non-depolarizing muscle relaxants. The applicable population covers surgical patients requiring muscle relaxation reversal, patients under long-term management of myasthenia gravis and patients with postoperative gastrointestinal motility disorder. 不对，哦第一句的“双重作用提升乙酰胆碱在突触间隙的浓度”哦对，我刚才漏了：哦修正第一句：As a commonly used anticholinesterase drug in clinical practice, neostigmine reversibly inhibits cholinesterase activity to reduce the degradation of acetylcholine, and directly stimulates nicotinic receptors on the motor endplate of skeletal muscle. Through these dual mechanisms, the concentration of acetylcholine in the synaptic cleft is increased, thus exerting a cholinomimetic effect. 哦对，这样更准。哦对，我刚才第一句：哦原句是：“作为临床常用的抗胆碱酯酶药物，新斯的明通过可逆性抑制胆碱酯酶活性，减少乙酰胆碱降解，同时可直接激动骨骼肌运动终板上的烟碱型受体，双重作用提升乙酰胆碱在突触间隙的浓度，从而发挥拟胆碱效应。哦对，翻译：As a commonly used anticholinesterase drug in clinical practice, neostigmine reversibly inhibits cholinesterase activity to reduce acetylcholine degradation, and directly stimulates nicotinic receptors on the motor endplate of skeletal muscle. The dual effects increase the concentration of acetylcholine in the synaptic cleft, thus exerting a cholinomimetic effect. 对，下一句：It is mainly used clinically for the long-term control of myasthenia gravis, and can also be used for the symptomatic treatment of postoperative functional intestinal flatulence and urinary retention. It is also often used as a conventional drug to antagonize the residual muscle relaxant effect of non-depolarizing muscle relaxants. The applicable population includes surgical patients requiring muscle relaxation reversal, patients under long-term management of myasthenia gravis and patients with postoperative gastrointestinal motility disorder. 对。然后第二段：The market size of domestic neostigmine哦：The market scale of domestic neostigmine preparations is stable at around 1.2 billion yuan, with a compound annual growth rate哦年复合增长率maintained at around 1.2 billion yuan, with a compound annual growth rate (CAGR) maintained in the range of 4% to 6%. Due to its early marketing time, the current domestic market is dominated by generic drug supply, and no original research products are sold in China. At present, more than 20 enterprises have been approved to produce neostigmine methylsulfate injection, among which the top 3 enterprises in terms of market share account for more than 70% of the total market share. Against the background of centralized drug procurement, the stable supply of active pharmaceutical ingredients (APIs) has become one of the core competitiveness of preparation enterprises. 对。哦对，“由于上市时间较早，当前国内市场以仿制药供应为主，暂无原研产品在华销售。哦对：哦正确的明由于其建立起，国内暂未有原研产品在华销售，哦对，翻译：The market size of domestic neostigmine preparations is stable at around 1.2 billion yuan, with a compound annual growth rate maintained in the range of 4% to 6%. Due to its early launch, the current domestic market is dominated by generic drug supply, and no original reference listed drug (RLD) are sold in China. At present, more than 20 enterprises have been approved to produce neostigmine methylsulfate injection, among which the top 3 enterprises in market share account for more than 70% of the total market. Against the background of centralized drug procurement, the stable supply of active pharmaceutical ingredients (APIs) has become one of the core competitiveness of preparation enterprises. 对。第三段：The original R&D enterprise of neostigmine is Roche, with the original trade name Prostigmin, and its core compound patents have expired in all major global markets. The current mainstream clinical dosage form is neostigmine methylsulfate injection, with common specifications of 1ml:0.5mg and 2ml:1mg. This variety has been listed as a reference preparation in the National Catalogue of Listed Drugs in China. A total of 7 registration numbers for neostigmine methylsulfate API have been approved in China, among which 5 are in A status, more than 30 domestic neostigmine methylsulfate injection preparations have been approved for marketing. (Data as of October 2025, for the latest information, please refer to the official website of CDE.)哦对，“该品种已列入中国上市药品目录集参比制剂”哦对，我刚才漏了：哦对，第三段：The original developer of neostigmine is Roche, with the original trade name Prostigmin, and its core compound patents have expired in all major global markets. At present, the mainstream clinical dosage form is neostigmine methylsulfate injection, with common specifications of 1ml:0.5mg and 2ml:1mg. This variety has been included in the reference preparations of the Catalogue of Listed Drugs in China. A total of 7 registration numbers for neostigmine methylsulfate API have been approved in China, among which 5 are in A status, and more than 30 domestic

新斯的明原研企业为罗氏，原研商品名为Prostigmin，核心化合物专利在全球主要市场均已到期。目前临床主流剂型为甲硫酸新斯的明注射液，常见规格为1ml:0.5mg、2ml:1mg。该品种已列入中国上市药品目录集参比制剂，国内共获批7个甲硫酸新斯的明原料药登记号，其中5个为A状态，另有超过30个国产甲硫酸新斯的明注射液制剂获批上市。（数据截至2025年10月，最新请以CDE官网为准）

CATO/佳途科技可提供新斯的明全系列杂质标准品，产品符合中国药典、FDA等多法规体系要求，大部分杂质可现货供应，现货订单16:00前下单即可当日发出，能够快速响应制剂研发、质量研究及常规质控环节的对照品需求。